Marinomed Biotech: Creditors Unanimously Approve Restructuring Plan

• Marinomed Biotech AG's restructuring plan was unanimously approved by creditors at the Korneuburg Regional Court.
• The restructuring plan includes a 30% quota payable in several tranches over two years, with a 5% cash deposit.
• Liquidity for repayment will be partially funded by selling the Carragelose business unit.
• A super quota of up to 7% will be distributed if milestone payments from the Carragelose sale exceed expectations within two years.
• Confirmation of the restructuring plan requires a 5% cash deposit and a standstill declaration from the European Investment Bank (EIB).
• Marinomed Biotech AG will provide updates on further developments.

The price of Marinomed Biotech at the time of the news was 8,1300EUR and was down -1,57 % compared with the previous day.

Marinomed Biotech

+3,47 %

+36,34 %

+94,96 %

+187,14 %

-51,90 %

-82,11 %

-84,46 %

-78,16 %

ISIN:ATMARINOMED6WKN:A2N9MM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max